S. Jeay

发表

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation

P. Kelly, S. Jeay, M. Llovera, 2000, Oncogene.

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition

Chris Jones, F. Hofmann, S. Robinson, 2012, Proceedings of the National Academy of Sciences.

The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1

Ensar Halilovic, S. Jeay, J. Wuerthner, 2016, Neuroendocrinology.

ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells

S. Jeay, C. Li, D. Leggett, 2007 .

The Proliferative and Antiapoptotic Actions of Growth Hormone and Insulin-Like Growth Factor-1 Are Mediated through Distinct Signaling Pathways in the Pro-B Ba/F3 Cell Line.

P. Kelly, S. Jeay, E. Baixeras, 2001, Endocrinology.

Prolactin and Growth Hormone Receptors

S. Jeay, L. Yu-Lee, 2002 .

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

C. Emery, S. Roman-Roman, Ensar Halilovic, 2016, Oncotarget.

Growth hormone prevents apoptosis through activation of nuclear factor-kappaB in interleukin-3-dependent Ba/F3 cell line.

G. Sonenshein, S. Jeay, E. Baixeras, 2000, Molecular endocrinology.

Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B.

G. Sonenshein, S. Jeay, H. Kagan, 2003, Molecular and cellular biology.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

S179D-Human PRL, a Pseudophosphorylated Human PRL Analog, Is an Agonist and Not an Antagonist.

J. Martial, P. Kelly, S. Jeay, 2001, Endocrinology.

S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.

J. Martial, P. Kelly, S. Jeay, 2001, Endocrinology.

Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Chris Jones, F. Hofmann, S. Jeay, 2011, Molecular Cancer Therapeutics.

Preclinical Development Enhanced Efficacy of IGF 1 R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFR a / b

Chris Jones, F. Hofmann, S. Jeay, 2011 .

c‐Myc represses FOXO3a‐mediated transcription of the gene encoding the p27Kip1 cyclin dependent kinase inhibitor

M. Wu, G. Sonenshein, S. Jeay, 2008, Journal of cellular biochemistry.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies

G. Demetri, R. Dummer, S. Ferretti, 2021, British Journal of Cancer.

Reciprocal Control of Forkhead box O 3a and c-Myc via the Phosphatidylinositol 3-Kinase Pathway Coordinately Regulates p27Kip1 Levels1

G. Sonenshein, S. Jeay, Vidyalakshmi Chandramohan, 2004, The Journal of Immunology.

Levels Kip 1 Pathway Coordinately Regulates p 27 c-Myc via the Phosphatidylinositol 3-Kinase Reciprocal Control of Forkhead box O 3 a and Pianetti and

G. Sonenshein, S. Jeay, S. Pianetti, 2004 .

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

W. Sellers, Nanxin Li, D. Ruddy, 2017, eLife.

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf−/− mouse model

Eric Y. Durand, J. Lehár, W. Sellers, 2017, Proceedings of the National Academy of Sciences.

Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.

M. P. Dillon, P. Atadja, E. Li, 2022, Journal of medicinal chemistry.

Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways

P. Kelly, G. Sonenshein, S. Jeay, 2002, Molecular and Cellular Endocrinology.

Growth Hormone Exerts Antiapoptotic and Proliferative Effects through Two Different Pathways Involving Nuclear Factor-κB and Phosphatidylinositol 3-Kinase** This work was supported by INSERM, a grant from Association pour la Recherche sur le Cancer, and USPHS Grant CA-36355 from the NIH.

P. Kelly, G. Sonenshein, S. Jeay, 2001, Endocrinology.

Growth Hormone Exerts Antiapoptotic and Proliferative Effects through Two Different Pathways Involving Nuclear Factor-k B and Phosphatidylinositol 3-Kinase *

P. Kelly, G. Sonenshein, S. Jeay, 2000 .

Driven Breast Cancer − Propeptide Reverses the Invasive Phenotype of Her-2 / neu The Tumor Suppressor Activity of the Lysyl Oxidase

G. Sonenshein, K. Kirsch, S. Jeay, 2007 .

The Propeptide Domain of Lysyl Oxidase Induces Phenotypic Reversion of Ras-transformed Cells*

P. Sommer, G. Sonenshein, S. Jeay, 2004, Journal of Biological Chemistry.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

M. Wiesmann, J. Griffin, Irene Simkin, 2015, Molecular Cancer Therapeutics.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.

Joel Greshock, Levi A Garraway, Fred Harbinski, 2016, Cancer research.

Growth Hormone (GH) and Prolactin Receptors in Human Peripheral Blood Mononuclear Cells: Relation with Age and GH-Binding Protein.

S. Jeay, Zida Wu, J. Bresson, 1999, Endocrinology.

Abstract CT152: Phase I dose- and regimen-finding study of NVP-HDM201 in pts with advancedTP53wt acute leukemias

D. DeAngelo, Ensar Halilovic, S. Jeay, 2017 .

New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity

P. Kelly, S. Jeay, V. Goffin, 2003, Endocrine.

The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.

G. Sonenshein, K. Kirsch, S. Jeay, 2007, Cancer research.

The proliferative and antiapoptotic actions of growth hormone and insulin-like growth factor-1 are mediated through distinct signaling pathways in the Pro-B Ba/F3 cell line.

P. Kelly, S. Jeay, E. Baixeras, 2001, Endocrinology.

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

S. Jeay, C. Li, D. Leggett, 2010, Molecular Cancer Therapeutics.

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Philipp Holzer, P. Furet, P. Chène, 2016, Bioorganic & medicinal chemistry letters.

Lysyl Oxidase Inhibits Ras-Mediated Transformation by Preventing Activation of NF-κB

G. Sonenshein, S. Jeay, H. Kagan, 2003, Molecular and Cellular Biology.

B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain

Robert E. Lewis, G. Sonenshein, S. Jeay, 2003, Oncogene.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Philipp Holzer, P. Furet, S. Ferretti, 2018, Bioorganic & medicinal chemistry letters.

Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma

G. Caponigro, R. Schlegel, M. Wiesmann, 2014 .

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.

E. Jacoby, Philipp Holzer, P. Furet, 2015, Bioorganic & medicinal chemistry letters.

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

C. Schnell, P. Furet, S. Jeay, 2016, Bioorganic & medicinal chemistry letters.

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

S. Jeay, C. Li, D. Leggett, 2010, Molecular Cancer Therapeutics.

Growth hormone exerts antiapoptotic and proliferative effects through two different pathways involving nuclear factor-kappaB and phosphatidylinositol 3-kinase.

P. Kelly, G. Sonenshein, S. Jeay, 2001, Endocrinology.

Predictive Power of Time-Series Based Machine Learning Models for DMPK Measurements in Drug Discovery

Thomas Sander, Modest von Korff, Olivier Corminboeuf, 2019, ICANN.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Dennie T. Frederick, G. Caponigro, M. Herlyn, 2017, Cell reports.

A Comprehensive Patient-Derived Xenograft Collection A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Representing the Heterogeneity of Melanoma.

Dennie T. Frederick, G. Caponigro, M. Herlyn, 2022 .

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

c‐Myc represses FOXO3a‐mediated transcription of the gene encoding the p27Kip1 cyclin dependent kinase inhibitor

M. Wu, G. Sonenshein, S. Jeay, 2008, Journal of cellular biochemistry.